Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 1, 2009, Pages 32-37

  Huang, Mingfang ^a   Gai, Xiaobo ^a   Yang, Xiangyue ^a   Hou, Jianping ^a   Lan, Xiaopeng ^a   Zheng, Weixing ^a   Chen, Fengping ^a   He, Jiake ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Angiotensin converting enzyme (ACE); Atrial fibrillation; CYP11B2; Hypertensive heart disease; Polymorphism

Indexed keywords

ALDOSTERONE SYNTHASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; RESTRICTION ENDONUCLEASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALDOSTERONE SYNTHASE; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 58149234038     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.023     Document Type: Article

References (37)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J Am Med Assoc 2003;290:199-206.
3. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41:218-23.
4. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11.
5. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC, RACE Investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J 2007;28:741-51.
6. Kistler PM, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006;27:3045-56.
7. Choisy SC, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension 2007;49:498-505.
8. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
9. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-14.
10. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204.
11. Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003;26:295-8.
12. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004;109:1640-6.
13. Fatini C, Sticchi E, Gensini F, Gori AM, Marcucci R, Lenti M, et al. Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. Int J Cardiol 2007;120:59-65.
14. Bedi M, McNamara D, London B, Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 2006;3:808-12.
15. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
16. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88:906-9.
17. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227-35.
18. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-9.
19. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol 2004;217:67-74.
20. White PC, Hautanen A, Kupari M. Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. J Steroid Biochem Mol Biol 1999;69:409-12.
21. Brand E, Chatelain N, Mulatero P, Féry I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198-204.
22. Amir O, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 2008;102:326-9.
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
24. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
25. Rigat B, Hubert C, Corvol P, Soubrier S. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
26. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120-1.
27. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-11.
28. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
29. Kupfahl C, Pink D, Friedrich K, Zurbrügg HR, Neuss M, Warnecke C, et al. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000;46:463-75.
30. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008;117:344-55.
31. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004;165:1019-32.
32. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
33. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
34. Ocaranza MP, Díaz-Araya G, Carreño JE, Muñoz D, Riveros JP, Jalil JE, et al. Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol 2004;286:H498-506.
35. Takahashi T, Ueno H, Yasumoto K, Kagitani S, Tomoda F, Inoue H, et al. Angiotensin-converting enzyme-gene polymorphism is associated with collagen I synthesis and QT dispersion in essential hypertension. J Hypertens 2003;21:985-91.
36. Yamashita T, Hayami N, Ajiki K, Oikawa N, Sezaki K, Inoue M, et al. Is ACE gene polymorphism associated with lone atrial fibrillation? Jpn Heart J 1997;38:637-41.
37. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994;331:250-8.